Harmony Biosciences Holdings (HRMY) Income from Continuing Operations (2019 - 2026)
Harmony Biosciences Holdings recorded quarterly Income from Continuing Operations of 32488000.0 in Q1 2026, down 12.46% quarter-over-quarter from 37114000.0 in Q4 2025, and down 28.69% year-over-year from 45560000.0 in Q1 2025.
Harmony Biosciences Holdings' Income from Continuing Operations history runs 8 years deep, the most recent figure standing at 32488000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 28.69% year-over-year to 32488000.0; the TTM figure through Mar 2026 stood at 160243000.0 (down 12.04% YoY), while the FY2025 annual figure was 173315000.0, down 0.94% from the prior year.
- Income from Continuing Operations came in at 32488000.0 for Q1 2026 at Harmony Biosciences Holdings, down from 37114000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 87943000.0 in Q3 2022 to a low of 37434000.0 in Q4 2022.
- A 5-year average of 35596411.76 and a median of 37114000.0 in 2025 frame the typical range for Income from Continuing Operations.
- On a YoY basis, Income from Continuing Operations climbed as much as 1014.17% in 2022 and fell as far as 296.42% in 2022.
- Harmony Biosciences Holdings' Income from Continuing Operations stood at 37434000.0 in 2022, then surged by 171.08% to 26607000.0 in 2023, then soared by 196.69% to 78940000.0 in 2024, then plunged by 52.98% to 37114000.0 in 2025, then retreated by 12.46% to 32488000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 32488000.0, 37114000.0, and 50865000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Harmony Biosciences Holdings | 1.83 Bn | 1.19 Bn | 170.88 Mn | 32.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 32.49 Mn |
| Dec 31, 2025 | 37.11 Mn |
| Sep 30, 2025 | 50.87 Mn |
| Jun 30, 2025 | 39.78 Mn |
| Mar 31, 2025 | 45.56 Mn |
| Dec 31, 2024 | 78.94 Mn |
| Sep 30, 2024 | 46.09 Mn |
| Jun 30, 2024 | 11.59 Mn |
| Mar 31, 2024 | 38.33 Mn |
| Dec 31, 2023 | 26.61 Mn |
| Sep 30, 2023 | 38.46 Mn |
| Jun 30, 2023 | 34.30 Mn |
| Mar 31, 2023 | 29.49 Mn |
| Dec 31, 2022 | -37.43 Mn |
| Sep 30, 2022 | 87.94 Mn |
| Jun 30, 2022 | 23.53 Mn |
| Mar 31, 2022 | 21.49 Mn |
| Dec 31, 2021 | 19.06 Mn |
| Sep 30, 2021 | -9.62 Mn |
| Jun 30, 2021 | 14.12 Mn |
| Mar 31, 2021 | 7.39 Mn |
| Dec 31, 2020 | -208,000.00 |
| Sep 30, 2020 | 1.91 Mn |
| Jun 30, 2020 | -27,000.00 |
| Mar 31, 2020 | -38.62 Mn |
| Dec 31, 2019 | -36.44 Mn |
| Sep 30, 2019 | -31.90 Mn |